ZLDPF (Zealand Pharma AS) Debt-to-Equity : 0.04 (As of Sep. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Zealand Pharma AS Debt-to-Equity?

Zealand Pharma AS's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $2.37 Mil. Zealand Pharma AS's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $55.61 Mil. Zealand Pharma AS's Total Stockholders Equity for the quarter that ended in Sep. 2024 was $1,322.30 Mil. Zealand Pharma AS's debt to equity for the quarter that ended in Sep. 2024 was 0.04.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Zealand Pharma AS's Debt-to-Equity or its related term are showing as below:

ZLDPF' s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.29 Max: 2.9
Current: 0.04

During the past 13 years, the highest Debt-to-Equity Ratio of Zealand Pharma AS was 2.90. The lowest was 0.00. And the median was 0.29.

ZLDPF's Debt-to-Equity is ranked better than
75.9% of 1025 companies
in the Biotechnology industry
Industry Median: 0.14 vs ZLDPF: 0.04

Zealand Pharma AS Debt-to-Equity Historical Data

The historical data trend for Zealand Pharma AS's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zealand Pharma AS Debt-to-Equity Chart

Zealand Pharma AS Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.07

0.11

0.85

0.54

0.08

Zealand Pharma AS Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Debt-to-Equity	Get a 7-Day Free Trial															0.06	0.08	0.14	0.04	0.04

Competitive Comparison of Zealand Pharma AS's Debt-to-Equity

For the Biotechnology subindustry, Zealand Pharma AS's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zealand Pharma AS's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zealand Pharma AS's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Zealand Pharma AS's Debt-to-Equity falls into.

Zealand Pharma AS Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Zealand Pharma AS's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.437	+	15.008)	/	233.048
	=	0.07

Zealand Pharma AS's Debt to Equity Ratio for the quarter that ended in Sep. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.372	+	55.605)	/	1322.295
	=	0.04

Zealand Pharma AS (OTCPK:ZLDPF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Zealand Pharma AS Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Zealand Pharma AS's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Zealand Pharma AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zealand Pharma AS (OTCPK:ZLDPF) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

ZEALc:UK 0NZU:UK ZEAL:Denmark 22Z:Germany

Address

Sydmarken 11, Soborg, DNK, DK-2860

Website

https://www.zealandpharma.com

Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.